Monitor for actual execution of these sales on Form 4 filings. The combined Atlas Venture filings, alongside 9 other insider sells in the past 30 days totaling $10.2M, suggest a pattern of insider distribution. While the dollar amount is not large relative to market cap, the signal from a lead venture investor trimming is notable. Watch for any clinical data readouts or pipeline updates that could alter the selling rationale.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $22.21entry
- T+1 · 5mo ago −1.89%α −1.76% · $21.79
- T+5 · 4mo ago +2.84%α +2.23% · $22.84
- T+20 · 4mo ago +15.40%α +16.43% · $25.63
- T+60 · 8w ago −26.92%α −29.74% · $16.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund I, L.P., two affiliated venture capital funds, filed Form 144 notices on June 29, 2026, indicating intent to sell a combined 102,969 shares of Dyne Therapeutics (DYN) valued at approximately $2.16 million. As early investors, these sales represent a partial exit by a major insider, though the dollar amount is modest relative to DYN's $3.5B market cap.
Key Facts
- Atlas Venture Fund XI, L.P. files Form 144 to sell 102,969 shares of DYN common stock.
- Atlas Venture Opportunity Fund I, L.P. also files a Form 144 on the same date (share count not specified in available text).
- Total proposed sale value is approximately $2,156,170.86 based on the first filing.
- Shares were acquired in a private placement on July 31, 2020.
- The filing is an advance notice of intent to sell; the actual sale may not occur.
- Recent insider activity (30d) shows 9 sells totaling $10.2M, indicating ongoing insider selling pressure.
Financial Impact
Proposed sale of ~102,969 shares worth ~$2.16M, representing a small fraction of DYN's $3.5B market cap.
Risk Factors
- Insider selling by a major early investor may signal reduced confidence in near-term catalysts.
- Additional unregistered sales by affiliates could add overhang.
- The company has no approved products; clinical-stage biotech risk is elevated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (DYN), Batch item 1 | 0001628280-26-046094 |
| Document: 0001628280-26-046094-index.html | 0001628280-26-046093 |
| Document: 0001628280-26-046094.txt | 0001628280-26-046094 |
| 144 Filing (DYN), Batch item 4 | 0001628280-26-046093 |
Track record
54 reports on DYN
12 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers